Patent status of histone deacetylase inhibitors

Bibliography

• MILLER TA, WITTER DJ, BELVEDERE S: Histone deacetylase inhibitors. J. Med. Chem. (2003) 46 (24) :5097–5116.
   PubMed Web of Science ®Google Scholar
• CURTIN ML: Current patent status of histone deacetylase inhibitors. Expert Opin. Ther. Patents (2002) 12(9):1375–1384.
   Web of Science ®Google Scholar
• MARKS PA, MILLER T, RICHON VM: Histone deacetylases. Can: Opin. PharmacoL (2003) 3(4):344–351.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RIFKIND RA, RICHON VM, BRESLOW R, MILLER T, KELLY WK: Histone deacetylases and cancer: causes and therapies. Nat. Rev Cancer (2001) 1:194–202.
   PubMed Web of Science ®Google Scholar
• KELLY WK, O'CONNOR OA, MARKS PA: Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs (2002) 11(12):1695–1713.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RICHON VM, BRESLOW R, RIFKIND RA: Histone deacetylase inhibitors as new cancer drugs. Curr . Opin. Oncol (2001) 13(6):477–483.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RIFKIND RA, RICHON VM, BRESLOW R: Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res. (2001) 7(4):759–760.
   PubMed Web of Science ®Google Scholar
• MEINKE PT, LIBERATOR P: Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Carr: Med. Chem. (2001) 8(2):211–235.
   PubMed Web of Science ®Google Scholar
• GROZINGER CM, SCHREIBER SL: Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. (2002) 9(1):3–16.
   PubMedGoogle Scholar
• JUNG M: Inhibitors of histone deacetylase as new anticancer agents. Carr: Med. Chem. (2001) 8(12):1505–1511.
   PubMed Web of Science ®Google Scholar
• FINNIN MS, DONIGIAN JR, COHEN A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401(6749):188–193.
   PubMed Web of Science ®Google Scholar
• MATSUYAMA A, SHIMAZUT, SUMIDA Y et al.: Li vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO (2002) 21(24):6820–6831.
   PubMed Web of Science ®Google Scholar
• STERNSON SM, WONG JC, GROZINGER CM, SCHREIBER SL: Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. (2001) 3(26):4239–4242.
   PubMed Web of Science ®Google Scholar
• HAGGARTY SJ, KOELLER KM, WONG JC, GROZINGER CM, SCHREIBER SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sti. USA (2003) 100(8):4389–4394.
   Google Scholar
• SU GH, SOHN TA, RYU B, KERN SE: A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. (2000) 60:3137–3142.
   PubMed Web of Science ®Google Scholar
• GLASER KB, LI J, AAKRE ME et al.: Transforming growth factor P-mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Mol. Cancer Ther. (2002) 1(10):759–768.
   PubMed Web of Science ®Google Scholar
• WIECH NL-H H, LEA M, JUNG M et al: Characterization of the activity of the histone deacetylase inhibitor CG-1521. AACR 931r1 Annual Meeting (2002) Abstract 346.
   Google Scholar
• BOUCHAIN G, LEIT S, FRECHETTE S et al.: Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. " Med. Chem. (2003) 46(5):820–830.
   Google Scholar
• PEREZ LB, REMISZEWSKI SW, SAMBUCETTI LC et al.: Discovery and SAR of NVP-LAQ824: novel histone deacetylase inhibitor with M vitro and in vivo antitumor activity. Meeting of the American Association for Cancer Res. San Francisco, CA (2002).
   Google Scholar
• REMISZEWSKI SW, BOBADILLA M, BONTEMPO J et al.: Preclinical efficacy, toxicology and pharmacokinetics of NPV-LAQ824, a novel histone deacetylase inhibitor. 14th EORTC-NCI-AACR. Frankfurt 2002).
   Google Scholar
• KIM DK, LEE JY, KIM JH et al.: Synthesis and biological evaluation of 3-(4-substituted-phenyfl-N-hydroxy-2-propenamicdes, a new class of histone deacetylase inhibitors. J. Med. Chem. (2003) 46:(26):5745–5751.
   PubMed Web of Science ®Google Scholar
• UESATO S, KITAGAWA M, NAGAOKA Y et al.: Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. Bioorg. Med. Chem. Lett (2002) 12(10):1347–1349.
   PubMed Web of Science ®Google Scholar
• JUNG M, HOFFMANN, K., BROSCH, G., LOID, P: Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (1997) 7(13):1655–1658.
   Google Scholar
• ARTS J, VAN ELELEN K, ANGIBAULD P et al.: Small molecule inhibitors of histone deacetylases (HDACs): Identification of JNJ16241199, a potent oral antitumoral agent. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics (2003) A153.
   Google Scholar
• CHEN JS, FALLER DV, R.A. S: Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer. Can: Cancer Drug Targets (2003) 3(3):219–236.
   Google Scholar
• REPHAELI A, ZHUK R, NUDELMAN A: Prodrugs of butyric acid from bench to bedside: synthetic design, mechanism of action, and clinical applications. Drug Dev. Res. (2000) 50(379–391)
   Web of Science ®Google Scholar
• CUMMINGS JI: Short chain fatty acids in the human colon. Cut (1981) 22:763–779.
   Google Scholar
• WATSON J, GLASG MB: Butyric acid in the treatment of cancer. Lancet (1933):746–748.
   Google Scholar
• GOTTLICHER M, MINUCCI S, ZHU P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO (2001) 20(24)6969–6978.
   Google Scholar
• JEONG MR, HASHIMOTO R, SENATOROV VV et al.: Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. (2003) 542(1-3):74–78.
   PubMed Web of Science ®Google Scholar
• PHIEL CJ, ZHANG F, HUANG EY et al.: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Biol. Chem. (2001) 276(39):36734–36741.
   Web of Science ®Google Scholar
• LEA MAR, VERRELL M, HODGE S, SHAUNA K: Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogs. Anti-Cancer Res. (1999) 19(3A):1971–1976.
   Google Scholar
• SUZUKI T, ANDO T, TSUCHIYA K et al.: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. Med. Chem. (1999) 42(15):3001–3003.
   Web of Science ®Google Scholar
• EL-BELTAGI HM, MARTENS ACM, LELIEVELD P, HAROUN EA, HAGENBEEK A: Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells-preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res. (1993) 53(13):3008–3014.
   PubMed Web of Science ®Google Scholar
• SEELIG MH, BERGER MR: Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Lid. J. Cancer (1996) 32A(11):1968–1976.
   Web of Science ®Google Scholar
• FOURNEL M, TRACHY-BOURGET MC, YAN PT et al.: Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. (2002) 62(15):4325–4330.
   PubMed Web of Science ®Google Scholar
• GLASER KB, STAVER MJ, WARING JFet al.: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Thec (2003) 2(2):151–163.
   Google Scholar
• FREY RR, WADA CK, GARLAND RB et al.: Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett (2002) 12(23):3443–3447.
   PubMed Web of Science ®Google Scholar
• FREY RR, CURTIN ML, GARLAND RB et al. Electrophilic ketone-based histone deacetylase (HDAC) inhibitors as cancer chemotherapeutic agents. ACS (2002) MED1121.
   Google Scholar
• MARSHALL JL, RIZVI N, KAUH J et al.: A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. The]: Oncol. (2002) 2(6):325–332.
   PubMedGoogle Scholar
• SANDOR V, BAKKE S, ROBEY RW et al: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Gin. Cancer Res. (2002) 8(3):718–728.
   Web of Science ®Google Scholar
• YUREK- GEORGEAH, BRIMMELL M, PACKHAM G, GANESAN A.: Total synthesis of spiruchostatin a, a potent histone deacetylase inhibitor. J. Am. Chem. Soc. (2004) 126(4):1030–1031.
   Google Scholar
• CHEN Y, GAMBS C, ABE Y, WENT WORTH P Jr, JANDA KD: Total Synthesis of the Depsipeptide FR-901375. J. Org. Chem. (2003) 68(23):8902–8905.
   PubMed Web of Science ®Google Scholar
• FURUMAI R, MATSUYAMA A, KOBASHI N et al.: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. (2002) 62(17):4916–4921.
   PubMed Web of Science ®Google Scholar
• NISHINO N, JOSE B, OKAMURA S et al.: Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. Org. Lett. (2003) 5(26):5079–5082.
   PubMed Web of Science ®Google Scholar
• FURUMAI R, KOMATSU Y, NISHINO N et al.: Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Nati Acad. Sci. USA (2001) 98(1):87–92.
   PubMed Web of Science ®Google Scholar
• KOMATSU Y, TOMIZAKI KY, TSUKAMOTO M et al.: Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. (2001) 61(11):4459–4466.
   PubMed Web of Science ®Google Scholar
• SINGH SB, ZINK DL, POLISHOOK JD, DOMBROWSKI AW, DARKIN-RATTRAY SJ, SCHMATZ DM, GOETZ MA: Apicidins: novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum. Tetrahedron Lett. (1996) 37(45)8077–8080.
   Google Scholar
• SINGH SB, ZINK DL, LIESCH JM et al: Structure, histone deacetylase, and antiprotozoal activities of apicidins B and C, congeners of apicidin with proline and valine substitutions. Org. Lett. (2001) 3(18):2815–2818.
   PubMed Web of Science ®Google Scholar
• SINGH SB, ZINK DL, LIESCH JM et al: Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal a-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. Org. Chem. (2002) 67(3):815–825.
   PubMed Web of Science ®Google Scholar
• COLLETTI SL, MYERS RW, DARKIN-RATTRAY SJ et al: Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2. Bioorg. Med. Chem. Lett. (2001) 11(2):113–117.
   Google Scholar
• COLLETTI SL, MYERS RW, DARKIN-RATTRAY SJ et al.: Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. Bioorg. Med. Chem. Lett. (2001) 11(2):107–111.
   Google Scholar